Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older
Zorginstituut Nederland (ZIN)
Record ID 32018001146
Authors' objectives: This is the pharmaceutical Joint Assessment PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. In October, 2020, the European Commission granted conditional marketing authorisation for Adakveo® (crizanlizumab) for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. Publication of this PTJA10 was postponed by 5 weeks due to the unavailability of the EPAR. This Joint Assessment aims to compare the clinical effectiveness and safety of crizanlizumab in the target patient populations with relevant comparators according to the national requirements of EUnetHTA partners.
Project Status: Completed
URL for project: https://eunethta.eu/ptja10/
Year Published: 2020
URL for published report: https://eunethta.eu/ptja10/
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
- Anemia, Sickle Cell
- Antibodies, Monoclonal, Humanized
Organisation Name: European Network for Health Technology Assessment
Contact Email: email@example.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.